/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE SERVICES./
TORONTO, Nov. 25, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce the following:
Biosign Schedules Investor Conference Call
Biosign is pleased to announce an Investor Conference Call, scheduled for Wednesday, November 27th, 2013 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared statement commenting on recent news releases and providing additional discussion on the Company's business plan. Following this presentation, Mr. Kaul will answer a number of questions previously submitted from participants regarding the business of the Company.
The conference call is open to any investor or stakeholder, including shareholders, broker-dealers and other securities professionals. The call will be recorded and available for review at http://biosign.com/investors. To submit one or more questions to the CEO, please email your question to [email protected] with the words "Investor Question for Conference Call" in the subject line. Biosign management will endeavour to address as many questions as possible in the one-hour time period allocated to the call. To participate in the call, please use the following login credentials:
Dial-In Number: 877-394-5901
Participant Code: 2169148
Date: November 27th, 2013 at 11:00 AM EDT
Biosign CEO Robert Kaul stated, "Throughout November, Biosign has made a number of material announcements related to our business plan. Management is pleased to be able to communicate with investors and other interested parties in order to place these announcements into greater context, and to address various stakeholder inquiries."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information:
Chief Executive Officer
Phone: (416) 218-9800 ext. 201
Email: [email protected]